Hyperion DeFi (NASDAQ:HYPD) versus Neuren Pharmaceuticals (OTCMKTS:NURPF) Critical Survey

Hyperion DeFi (NASDAQ:HYPD) and Neuren Pharmaceuticals (OTCMKTS:NURPF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Valuation and Earnings

This table compares Hyperion DeFi and Neuren Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810,000.00	46.40	-$45.31 million	($11.80)	-0.28
Neuren Pharmaceuticals	N/A	N/A	N/A	C($0.01)	-919.05

Neuren Pharmaceuticals has lower revenue, but higher earnings than Hyperion DeFi. Neuren Pharmaceuticals is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 1.7% of Neuren Pharmaceuticals shares are held by institutional investors. 10.9% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Hyperion DeFi and Neuren Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2	0	2	0	2.00
Neuren Pharmaceuticals	0	0	0	0	0.00

Hyperion DeFi currently has a consensus target price of $5.88, indicating a potential upside of 78.03%. Given Hyperion DeFi’s stronger consensus rating and higher possible upside, research analysts clearly believe Hyperion DeFi is more favorable than Neuren Pharmaceuticals.

Profitability

This table compares Hyperion DeFi and Neuren Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-138.16%	-94.12%
Neuren Pharmaceuticals	N/A	N/A	N/A

Summary

Hyperion DeFi beats Neuren Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.